Washington University has a long history of research in the area of imaging. Investigations on the clinical application of the first computed tomography scanner were carried out at Washington University and positron emission tomography was initially developed here. The Oncologic Imaging Program emphasizes the developmental of novel imaging agents for nuclear imaging, MR imaging and optical imaging, as well as the application of a variety of imaging techniques to oncologic problems. The Program's research is focused in the following areas: (1) the development of new imaging agents to assess tumor therapy, 92) the investigation of agents designed to monitor multi-drug resistant modulators, (3) the development of new techniques in the area of molecular imaging, (4) the development of agents initially designed for oncologic imaging and extending their application to therapy with unsealed sources, and (5) the application for modern imaging techniques for the evaluation and planning of radiation treatment. Several research questionnaires are common to all of these areas. A major effort is being made in developing co-registration techniques for the various imaging modalities that can be utilized in small animal models of cancer, large animal imaging as well as human imaging. The Oncologic Imaging Program has the goal of expanding collaboration on the application of imaging techniques to answer specific questions in the other Programs. The Program is applying its expertise in small animal imaging to collaborations with the basic science Programs as well as translating basic science investigation to the Clinical and Translational Research Program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
1P30CA091842-01
Application #
6500123
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2001-08-02
Project End
2004-06-30
Budget Start
Budget End
Support Year
1
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Washington University
Department
Type
DUNS #
062761671
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Betleja, Ewelina; Nanjundappa, Rashmi; Cheng, Tao et al. (2018) A novel Cep120-dependent mechanism inhibits centriole maturation in quiescent cells. Elife 7:
Chen, Li-Shiun; Horton, Amy; Bierut, Laura (2018) Pathways to precision medicine in smoking cessation treatments. Neurosci Lett 669:83-92
Celik, Hamza; Koh, Won Kyun; Kramer, Ashley C et al. (2018) JARID2 Functions as a Tumor Suppressor in Myeloid Neoplasms by Repressing Self-Renewal in Hematopoietic Progenitor Cells. Cancer Cell 34:741-756.e8
Olfson, Emily; Bloom, Joseph; Bertelsen, Sarah et al. (2018) CYP2A6 metabolism in the development of smoking behaviors in young adults. Addict Biol 23:437-447
Hirbe, Angela C; Jennings, Jack; Saad, Nael et al. (2018) A Phase II Study of Tumor Ablation in Patients with Metastatic Sarcoma Stable on Chemotherapy. Oncologist 23:760-e76
Jenkins, Wiley D; Gilbert, David; Chen, Li-Shiun et al. (2018) Finding paths with the greatest chance of success: enabling and focusing lung cancer screening and cessation in resource-constrained areas. Transl Lung Cancer Res 7:S261-S264
Kabir, Ashraf Ul; Lee, Tae-Jin; Pan, Hua et al. (2018) Requisite endothelial reactivation and effective siRNA nanoparticle targeting of Etv2/Er71 in tumor angiogenesis. JCI Insight 3:
Smith, Lee; Ae Lee, Jung; Mun, Junbae et al. (2018) Levels and patterns of self-reported and objectively-measured free-living physical activity among prostate cancer survivors: A prospective cohort study. Cancer :
Burclaff, Joseph; Mills, Jason C (2018) Plasticity of differentiated cells in wound repair and tumorigenesis, part II: skin and intestine. Dis Model Mech 11:
Cherian, Mathew A; Olson, Sydney; Sundaramoorthi, Hemalatha et al. (2018) An activating mutation of interferon regulatory factor 4 (IRF4) in adult T-cell leukemia. J Biol Chem 293:6844-6858

Showing the most recent 10 out of 1244 publications